You searched for: hydroxycarbamide (Engelska - Maltesiska)

siklos hydroxycarbamide
siklos idrossikarbammid

siklos 1000 mg tablets hydroxycarbamide
siklos 1000 mg, pilloli hydroxycarbamide

urea is one metabolite of hydroxycarbamide.
urea huwa metabolit wieħed ta ’ hydroxycarbamide.

each tablet contains 1000 mg hydroxycarbamide
kull pillola fiha 1000 mg hydroxycarbamide

hydroxycarbamide is excreted in human milk.
hydroxycarbamide jitneħħa fil-ħalib tal-bniedem.

siklos 100 mg tablets hydroxycarbamide oral use
siklos 100 mg pilloli hydroxycarbamide użu orali

each tablet contains 100 mg of hydroxycarbamide.
kull pillola fiha 100 mg ta’ hydroxycarbamide

siklos 100 mg film-coated tablets hydroxycarbamide
siklos 100 mg pilloli miksija b’rita hydroxycarbamide

hydroxycarbamide is presumed to be a transspecies carcinogen.
hydroxycarbamide hu maħsub li hu karċinoġenu fi speċi differenti.

each film-coated tablet contains 1000 mg hydroxycarbamide.
kull pillola miksija b’ rita fiha 1000 mg hydroxycarbamide.

specific interaction studies have not been performed with hydroxycarbamide.
ma sarux studji speċifiċi dwar l-effett ta’ mediċini jew ta’ affarijiet oħra fuq hydroxycarbamide.

however, hydroxycarbamide is presumed to be a transspecies carcinogen.
iżda, hydroxycarbamide hu meqjus bħala karċinoġenu fi speċi differenti.

hydroxycarbamide is unequivocally genotoxic in a wide range of test systems.
hydroxycarbamide huwa bla dubju ġenotossiku f' sensiela wiesa ’ ta ’ sistemi ta ’ analiżi.

an erythema caused by radiation therapy may be aggravated by hydroxycarbamide.
eritema kkawżata minn terapija ta’ radjazzjoni tista’ tiġi aggravata b’hydroxycarbamide.

the estimated volume of distribution of hydroxycarbamide approximates total body water.
il -

skin cancer has also been reported in patients receiving long-term hydroxycarbamide.
kanċer tal-ġilda ġie wkoll irrappurtat f’pazjenti li qed jirċievu hydroxycarbamide fit-tul.

2 the macrocytosis caused by hydroxycarbamide is not vitamin b12 or folic acid dependent.
2 il-makroċitożi kkawżata minn hydroxycarbamide mhijiex dipendenti fuq vitamina b12 jew aċidu foliku.

patients on hydroxycarbamide should be made aware of the theoretical risks to the foetus.
pazjenti li qed jieħdu hydroxycarbamide għandu jingħatalhom parir biex isiru konxji mir-riskji teoretiċi lil fetu.

vaccination with a live vaccine in a patient taking hydroxycarbamide may result in severe infections.
vaċċinazzjoni b’vaċċin ħaj f’pazjent li qed jieħu hydroxycarbamide tista’ tirriżulta f’infezzjoni serja.

conventional long-term studies to evaluate the carcinogenic potential of hydroxycarbamide have not been performed.
ma sarux studji konvenzjonali fit-tul biex jistudjaw il-potenzjal karċinoġeniku ta’ hydroxycarbamide.